Aims Emerging evidence has linked cholesterol metabolism with platelet responsiveness.
We sought to examine the dose–response relationship between low-density lipoprotein …

Optimal dual antiplatelet therapy (DAPT) strategy in high-bleeding risk (HBR) patients
presenting with acute coronary syndrome remains debated. We sought to investigate the …

Aims Ticagrelor is associated with a lower risk of ischemic events than clopidogrel.
However, it is uncertain whether the benefits of more intensive anti-ischemic therapy …

Background Major bleeding after acute coronary syndrome predicts a poor outcome but is
challenging to define. The choice of antiplatelet influences bleeding risk. Methods and …

Background The prospective observational CHANGE DAPT study compared clopidogrel
versus ticagrelor-based dual antiplatelet (DAPT) regimens in consecutive patients with acute …

The development of new oral antagonists of the platelet P2Y12 receptor has generated both
anticipation and anxiety among practising physicians. In a field in which clopidogrel was the …

Background After percutaneous coronary interventions (PCIs), patients remain at high risk of
developing late cardiovascular events. Although controlling low-density lipoprotein …

Objective To compare hemorrhagic events between clopidogrel and ticagrelor in the Platelet
Inhibition and Patient Outcomes (PLATO) trial. Methods We examined the FDA Medical …

Therapeutic Advances in Cardiovascular Disease 7 (1) 6 http://tac. sagepub. com ticagrelor's
favor. Indeed, the reporting of procedural bleeds was set up to be related to the procedure …

Introduction Dual antiplatelet therapy (DAPT), including potent P2Y12 inhibition after ST-
elevation myocardial infarction (STEMI) is recommended in clinical guidelines. However …